Resolution of warfarin-induced alopecia with conversion to apixaban
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ..
Warfarin is frequently prescribed as a long-term anticoagulant in patients with end-stage kidney disease as direct oral anticoagulants undergo renal excretion. Anticoagulation is a rare cause of alopecia in adults and is thought to be due to the promotion of the 'resting phase' of hair follicles. In this case report, a prevalent haemodialysis female patient required long-term anticoagulation following a complex pulmonary embolus and dialysis access complications. After commencing warfarin therapy, the patient reported generalised loss and thinning of her hair. All other potential causes were excluded. Cessation of warfarin therapy and conversion to apixaban with close monitoring alleviated the hair loss. Warfarin therapy is a rare cause of alopecia but should be considered in patients on long-term anticoagulation when other diagnoses have been excluded. Hair loss has a profoundly negative impact on patient quality of life and should prompt investigation to determine the underlying cause.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
BMJ case reports - 14(2021), 3 vom: 02. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hull, Katherine Leigh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 03.03.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bcr-2020-240579 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322113709 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322113709 | ||
| 003 | DE-627 | ||
| 005 | 20231225181338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bcr-2020-240579 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM322113709 | ||
| 035 | |a (NLM)33653862 | ||
| 035 | |a (PII)e240579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hull, Katherine Leigh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Resolution of warfarin-induced alopecia with conversion to apixaban |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 03.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Warfarin is frequently prescribed as a long-term anticoagulant in patients with end-stage kidney disease as direct oral anticoagulants undergo renal excretion. Anticoagulation is a rare cause of alopecia in adults and is thought to be due to the promotion of the 'resting phase' of hair follicles. In this case report, a prevalent haemodialysis female patient required long-term anticoagulation following a complex pulmonary embolus and dialysis access complications. After commencing warfarin therapy, the patient reported generalised loss and thinning of her hair. All other potential causes were excluded. Cessation of warfarin therapy and conversion to apixaban with close monitoring alleviated the hair loss. Warfarin therapy is a rare cause of alopecia but should be considered in patients on long-term anticoagulation when other diagnoses have been excluded. Hair loss has a profoundly negative impact on patient quality of life and should prompt investigation to determine the underlying cause | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic renal failure | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a haematology (drugs and medicines) | |
| 650 | 4 | |a renal system | |
| 650 | 4 | |a unwanted effects / adverse reactions | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a apixaban |2 NLM | |
| 650 | 7 | |a 3Z9Y7UWC1J |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 700 | 1 | |a Gooding, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, James O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ case reports |d 2008 |g 14(2021), 3 vom: 02. März |w (DE-627)NLM209291001 |x 1757-790X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:3 |g day:02 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bcr-2020-240579 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 3 |b 02 |c 03 | ||